Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma

Tao,Ran; Li,Qiang; Gao,Xiaofei; Ma,Lilin

doi:10.3892/ol.2018.8030

Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma

Authors:
- Ran Tao
- Qiang Li
- Xiaofei Gao
- Lilin Ma
View Affiliations

Affiliations: Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of General Surgery, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P.R. China, Department of Cardiology, The First People's Hospital of Hangzhou, Hangzhou, Zhejiang 310000, P.R. China
Published online on: February 12, 2018 https://doi.org/10.3892/ol.2018.8030
Pages: 5879-5886

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are a limited number of studies reporting on the expression of G protein‑coupled receptor kinase 6 (GRK6) in colorectal carcinoma (CRC). The aim of the present study was to investigate and examine the clinical value of GRK6 expression in human CRC. The expression of the GRK6 protein was determined in CRC tissues (n=83) and in normal colorectal tissues (n=19) by immunohistochemical (IHC) analysis. In addition, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was conducted to investigate GRK6 mRNA levels in matched pairs of cancerous and non‑cancerous fresh frozen tissues from 19 patients with CRC. Furthermore, GRK6 protein levels were evaluated in matched pairs of cancerous and non‑cancerous fresh frozen tissues from 19 other patients with CRC by western blot analysis. The expression of GRK6 was significantly upregulated in patients with CRC as indicated by IHC analysis (P=0.028). The results of RT‑qPCR and western blotting confirmed that GRK6 mRNA and protein levels were upregulated in CRC tissues compared with matched adjacent non-cancerous tissues (P<0.05). Additionally, GRK6 protein expression was significantly associated with histological differentiation (P=0.001), lymph node invasion (P=0.45), venous invasion (P=0.009), depth of invasion (P=0.026), distant metastasis (P<0.0001) and TNM stages (P=0.020). Survival analysis using the Kaplan‑Meier method indicated that patients with high GRK6 expression levels exhibited lower overall survival rates compared with patients with low GRK6 expression. Multivariate analysis using the Cox proportional hazards model indicated that the expression levels of GRK6 (P=0.003) were independent prognostic factors for overall survival in patients. The overexpression of GRK6 in patients with CRC may serve as an independent predictor of patient outcome.

View Figures

View References

1	Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, Saini JP, Gilberg F and Cunningham D: Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: A meta-analysis of individual data from 6171 patients. Ann Oncol. 22:2604–2609. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zeng H and Zhang S: The updated incidences and mortalities of major cancers in China, 2011. Chin J Cancer. 34:502–507. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sugarbaker PH: Second-look surgery for colorectal cancer: Revised selection factors and new treatment options for greater success. Int J Surg Oncol. 2011:9150782011.PubMed/NCBI
4	Liu QZ, Gao XH, Chang WJ, Gong HF, Fu CG, Zhang W and Cao GW: Expression of ITGB1 predicts prognosis in colorectal cancer: A large prospective study based on tissue microarray. Int J Clin Exp Pathol. 8:12802–12810. 2015.PubMed/NCBI
5	Uhry Z, Belot A, Colonna M, Bossard N, Rogel A, Iwaz J, Mitton N, Grosclaude P and Remontet L: National cancer incidence is estimated using the incidence/mortality ratio in countries with local incidence data: Is this estimation correct? Cancer Epidemiol. 37:270–277. 2013. View Article : Google Scholar : PubMed/NCBI
6	Alsop K, Mead L, Smith LD, Royce SG, Tesoriero AA, Young JP, Haydon A, Grubb G, Giles GG, Jenkins MA, et al: Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years. Eur J Cancer. 42:1357–1361. 2006. View Article : Google Scholar : PubMed/NCBI
7	Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm RA and van den Brandt PA: K-ras oncogene mutations in sporadic colorectal cancer in the netherlands cohort study. Carcinogenesis. 24:703–710. 2003. View Article : Google Scholar : PubMed/NCBI
8	Jimi S, Yasui T, Hotokezaka M, Shimada K, Shinagawa Y, Shiozaki H, Tsutsumi N and Takeda S: Clinical features and prognostic factors of bone metastases from colorectal cancer. Surg Today. 43:751–756. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lan YT, Chang SC, Yang SH, Lin CC, Wang HS, Jiang JK, Chen WS, Lin TC, Chiou SH and Lin JK: Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. Am J Surg. 207:922–930. 2014. View Article : Google Scholar : PubMed/NCBI
10	Vroon A, Heijnen CJ and Kavelaars A: GRKs and arrestins: Regulators of migration and inflammation. J Leukoc Biol. 80:1214–1221. 2006. View Article : Google Scholar : PubMed/NCBI
11	Raghuwanshi SK, Smith N, Rivers EJ, Thomas AJ, Sutton N, Hu Y, Mukhopadhyay S, Chen XL, Leung T and Richardson RM: G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression and metastasis. J Immunol. 190:5329–5336. 2013. View Article : Google Scholar : PubMed/NCBI
12	Dorn GW II: GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med. 87:455–463. 2009. View Article : Google Scholar : PubMed/NCBI
13	Metaye T, Gibelin H, Perdrisot R and Kraimps JL: Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal. 17:917–928. 2005. View Article : Google Scholar : PubMed/NCBI
14	Premont RT, Claing A, Vitale N, Freeman JL, Pitcher JA, Patton WA, Moss J, Vaughan M and Lefkowitz RJ: Beta2-Adrenergic receptor regulation by GIT1, a G protein-coupled receptor kinase-associated ADP ribosylation factor GTPase-activating protein. Proc Natl Acad Sci USA. 95:pp. 14082–14087. 1998; View Article : Google Scholar : PubMed/NCBI
15	Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, et al: Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med. 2:28ra282010. View Article : Google Scholar : PubMed/NCBI
16	Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, et al: Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood. 115:1594–1604. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yao S, Zhong L, Liu J, Feng J, Bian T, Zhang Q, Chen J, Lv X, Chen J and Liu Y: Prognostic value of decreased GRK6 expression in lung adenocarcinoma. J Cancer Res Clin Oncol. 142:2541–2549. 2016. View Article : Google Scholar : PubMed/NCBI
18	Li YP: GRK6 expression in patients with hepatocellular carcinoma. Asian Pac J Trop Med. 6:220–223. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yuan L, Zhang H, Liu J, Rubin JB, Cho YJ, Shu HK, Schniederjan M and MacDonald TJ: Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer. 12:182013. View Article : Google Scholar : PubMed/NCBI
20	Altman DG, McShane LM, Sauerbrei W and Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLoS Med. 9:e10012162012. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the american joint committee on cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
22	Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP Jr, Hall MJ, Llor X, Chung DC, Ahnen DJ, Bray T, et al: NCCN guidelines insights: Genetic/Familial high-risk assessment: Colorectal, 2008. J Natl Compr Canc Netw. 15:9–20. 2007.
23	Li Q, Zhi X, Zhou J, Tao R, Zhang J, Chen P, Røe OD, Sun L and Ma L: Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: A prospective study. Oncotarget. 7:36645–36654. 2016.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Shi R, Wang L, Wang T, Xu J, Wang F and Xu M: NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol. 31:8522014. View Article : Google Scholar : PubMed/NCBI
26	Tian Y, Xu T, Huang J, Zhang L, Xu S, Xiong B, Wang Y and Tang H: Tissue metabonomic phenotyping for diagnosis and prognosis of human colorectal cancer. Sci Rep. 6:207902016. View Article : Google Scholar : PubMed/NCBI
27	Ikeda K, Kojima M, Saito N, Sakuyama N, Koushi K, Watanabe T, Sugihara K, Akimoto T, Ito M and Ochiai A: Current status of the histopathological assessment, diagnosis and reporting of colorectal neuroendocrine tumors: A web survey from the japanese society for cancer of colon and rectum. Pathol Int. 66:94–101. 2016. View Article : Google Scholar : PubMed/NCBI
28	Shitara K, Mizota A, Yatabe Y, Kondo C, Nomura M, Yokota T, Takahari D, Ura T and Muro K: Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab. Jan J Clin Oncol. 41:663–665. 2011. View Article : Google Scholar
29	Chua TC and Merrett ND: Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer. 130:2845–2856. 2012. View Article : Google Scholar : PubMed/NCBI
30	Benovic JL and Gomez J: Molecular cloning and expression of GRK6. A new member of the G protein-coupled receptor kinase family. J Biol Chem. 268:19521–19527. 1993.PubMed/NCBI
31	Zhou Y, Li RJ, Li M, Liu X, Zhu HY, Ju Z, Miao X and Xu GY: Overexpression of GRK6 attenuates neuropathic pain via suppression of CXCR2 in rat dorsal root ganglion. Mol Pain. 12:17448069166463812016. View Article : Google Scholar : PubMed/NCBI
32	Willets JM, Challiss RA and Nahorski SR: Endogenous G protein-coupled receptor kinase 6 Regulates M3 muscarinic acetylcholine receptor phosphorylation and desensitization in human SH-SY5Y neuroblastoma cells. J Biol Chem. 277:15523–15529. 2002. View Article : Google Scholar : PubMed/NCBI
33	Chen Y, Lu B, Yang Q, Fearns C, Yates JR III and Lee JD: Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res. 69:3713–3720. 2009. View Article : Google Scholar : PubMed/NCBI
34	Ribas C, Penela P, Murga C, Salcedo A, García-Hoz C, Jurado-Pueyo M, Aymerich I and Mayor F Jr: The G protein-coupled receptor kinase (GRK) interactome: Role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 1768:913–922. 2007. View Article : Google Scholar : PubMed/NCBI